Drug mechanism-of-action + molecular target landscape for any disease — targets in active
Drug mechanism-of-action + molecular target landscape for any disease — targets in active trials, approved agents by MOA, crowded vs novel mechanisms and first-in-class openings, with key publications. Worldwide. For drug-discovery and VC agents.
200000 (raw units)
price
1
calls / 30d
1
unique payers
2026-08-20
updated
Provider
clinicalintelpulse.theaslangroupllc.com · discovered, not yet claimed by its owner
Payment (x402 accepts[])
[
{
"scheme": "exact",
"network": "eip155:8453",
"payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
"asset": "0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913",
"amount": "200000",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "eip155:8453",
"payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
"asset": "0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913",
"amount": "200000",
"maxTimeoutSeconds": 604900
},
{
"scheme": "exact",
"network": "solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp",
"payTo": "985iFjbnGQ3dJcwXnfRCMSrH4Jnc3kW1N6msR64B5KX1",
"asset": "EPjFWdd5AufqSSqeM2qN1xzybapC8G4wEGGkZwyTDt1v",
"amount": "200000",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "eip155:137",
"payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
"asset": "0x3c499c542cEF5E3811e1192ce70d8cC03d5c3359",
"amount": "200000",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "eip155:42161",
"payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
"asset": "0xaf88d065e77c8cC2239327C5EDb3A432268e5831",
"amount": "200000",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "eip155:480",
"payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
"asset": "0x79A02482A880bCe3F13E09da970dC34dB4cD24D1",
"amount": "200000",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "eip155:143",
"payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
"asset": "0x754704Bc059F8C67012fEd69BC8A327a5aafb603",
"amount": "200000",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "eip155:196",
"payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
"asset": "0x779ded0c9e1022225f8e0630b35a9b54be713736",
"amount": "200000",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "eip155:999",
"payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
"asset": "0xb88339CB7199b77E23DB6E890353E22632Ba630f",
"amount": "200000",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k",
"payTo": "62A253YPATFNJCPRKID3FKD77MYJFNTVRYRP4B4JWG36EGLPY7UXFWGI7I",
"asset": "31566704",
"amount": "200000",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "xrpl:0",
"payTo": "rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32",
"asset": "XRP",
"amount": "200000",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "xrpl:0",
"payTo": "rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32",
"asset": "524C555344000000000000000000000000000000",
"amount": "0.2",
"maxTimeoutSeconds": 300
},
{
"scheme": "exact",
"network": "eip155:56",
"payTo": "0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc",
"asset": "0x8d0D000Ee44948FC98c9B98A4FA4921476f08B0d",
"amount": "200000000000000000",
"maxTimeoutSeconds": 300
}
]Output schema
{
"bazaar": {
"info": {
"input": {
"method": "GET",
"queryParams": {
"condition": "Disease — e.g. \"Treatment-Resistant Depression\" | \"ALS\" | \"Lupus\" | \"Multiple Sclerosis\" | \"Prostate Cancer\"",
"lang": "en | es | fr | de | ja | zh | ko | pt | ar | hi (default: en)",
"mechanism": "Optional — specific mechanism to focus on, e.g. \"BTK inhibitor\" | \"IL-17\" | \"CAR-T\""
},
"type": "http"
},
"output": {
"example": {
"drug_discovery_implications": "BTK inhibition is the most clinically advanced novel mechanism. CNS penetration and microglial targeting differentiate from older agents. Progressive MS remains the largest unmet need.",
"first_in_class_opportunities": [
"BTK inhibitors for progression (if Phase 3 data positive)",
"Remyelinating agents (no approved class)"
],
"key_publications": [
{
"journal": "Nature Reviews Neurology",
"title": "BTK inhibitors in progressive MS — mechanisms and clinical data",
"year": "2024"
}
],
"mechanism_landscape": {
"approved_mechanisms": [
{
"drugs": [
"Ocrelizumab",
"Ofatumumab",
"Ublituximab"
],
"moa": "Anti-CD20 (B cell depletion)",
"notes": "Dominant mechanism for RRMS — 3 approved"
},
{
"drugs": [
"Fingolimod",
"Siponimod",
"Ozanimod",
"Ponesimod"
],
"moa": "S1P receptor modulator",
"notes": "Oral DMT — 4 approved; class mature"
},
{
"drugs": [],
"moa": "BTK inhibitor",
"notes": "No approvals yet — 6 agents in Phase 2/3"
}
],
"crowded_spaces": [
"Anti-CD20 (3 approved, 2 in pipeline)",
"S1P modulators (4 approved)",
"Natalizumab analogues"
],
"pipeline_mechanisms": [
{
"agents": [
"Fenebrutinib (Roche)",
"Tolebrutinib (Sanofi)",
"Evobrutinib (Merck)"
],
"crowding": "Moderate (3 Phase 3)",
"differentiation": "Targets microglial activation — may address progressive MS unlike existing agents",
"moa": "BTK inhibition (CNS-penetrant)",
"phase": "PHASE3"
},
{
"agents": [
"Opicinumab (Biogen)"
],
"crowding": "Low",
"differentiation": "Novel — no approved remyelinating agents",
"moa": "Remyelination (opioid receptor modulation)",
"phase": "PHASE2"
}
],
"white_spaces": [
"Progressive MS neuroprotection",
"Remyelination",
"CNS innate immunity",
"Biomarker-stratified precision approaches"
]
},
"query_summary": {
"condition": "Multiple Sclerosis",
"mechanism": null
}
},
"type": "json"
}
},
"schema": {
"$schema": "https://json-schema.org/draft/2020-12/schema",
"properties": {
"input": {
"additionalProperties": false,
"properties": {
"method": {
"enum": [
"GET",
"HEAD",
"DELETE"
],
"type": "string"
},
"queryParams": {
"properties": {
"condition": {
"type": "string"
},
"lang": {
"type": "string"
},
"mechanism": {
"type": "string"
}
},
"type": "object"
},
"type": {
"const": "http",
"type": "string"
}
},
"required": [
"type",
"method"
],
"type": "object"
},
"output": {
"properties": {
"example": {
"type": "object"
},
"type": {
"type": "string"
}
},
"required": [
"type"
],
"type": "object"
}
},
"required": [
"input"
],
"type": "object"
}
},
"builder-code": {
"info": {
"a": "bc_gxy6qn5p"
},
"schema": {
"$schema": "https://json-schema.org/draft/2020-12/schema",
"additionalProperties": false,
"properties": {
"a": {
"description": "App builder code",
"pattern": "^[a-z0-9_]{1,32}$",
"type": "string"
},
"s": {
"description": "Service builder codes",
"items": {
"pattern": "^[a-z0-9_]{1,32}$",
"type": "string"
},
"type": "array"
},
"w": {
"description": "Wallet builder code",
"pattern": "^[a-z0-9_]{1,32}$",
"type": "string"
}
},
"type": "object"
}
}
}Use it
curl
curl "https://clinicalintelpulse.theaslangroupllc.com/api/clinical/mechanism-map" # -> 402 Payment Required, accepts[] lists how to pay # retry with a PAYMENT-SIGNATURE (or PAYMENT header) once paid
JavaScript
const res = await fetch("https://clinicalintelpulse.theaslangroupllc.com/api/clinical/mechanism-map");
if (res.status === 402) {
const { accepts } = await res.json();
// pay one of accepts[] via an x402 client, then retry with the payment header
}Python
import httpx
res = httpx.get("https://clinicalintelpulse.theaslangroupllc.com/api/clinical/mechanism-map")
if res.status_code == 402:
accepts = res.json()["accepts"]
# pay one of accepts[] via an x402 client, then retry with the payment headerMachine-readable
Everything on this page is also available as clean JSON at /resources/4548.json, and this resource appears in /discovery/resources and /discovery/search.